Overview
Piracetam (2-oxo-1-pyrrolidine acetamide) is a cyclic derivative of GABA synthesized by UCB Pharma in 1964 and the founding member of the racetam class of nootropics. Despite its GABA-like structure, piracetam does not bind GABA receptors and has no sedative or anticonvulsant activity in the classical sense.
It is approved in many European, Asian, and South American countries for cortical myoclonus, age-related cognitive decline, post-stroke aphasia, and vertigo. It is not FDA-approved in the United States and cannot be sold as a dietary supplement, though it is widely used off-label.
Clinical evidence supports modest cognitive benefits in dementia and post-stroke recovery, with the strongest data in cortical myoclonus where it produces clinically significant reductions in jerk severity. The mechanism remains incompletely understood but involves membrane fluidity, AMPA receptor modulation, and improved microcirculation.
Quick facts
- Mechanism
- AMPA receptor modulator that improves neuronal membrane fluidity and cerebral microcirculation
- Primary use
- Cortical myoclonus, age-related cognitive decline, post-stroke recovery
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral (most common); IV in hospital settings
- Typical results
- Modest improvements in cognition in dementia and post-stroke aphasia; meaningful reductions in cortical myoclonus
Chemical information
Piracetam (C₆H₁₀N₂O₂) is a nootropic compound with a molecular weight of 142.16 g/mol. Its structural characteristics underpin its biological activity in cognitive enhancement and neuroprotection.
How Piracetam works
Piracetam interacts with phospholipid head groups in neuronal membranes, restoring membrane fluidity that decreases with aging and oxidative stress. It positively modulates AMPA-type glutamate receptors, enhancing excitatory neurotransmission without direct agonism. It also reduces platelet aggregation and erythrocyte rigidity, improving cerebral microcirculation.
At the membrane level, piracetam binds polar phospholipid heads and reorganizes membrane microdomains, restoring fluidity in aged or damaged neurons. This rheological effect may underlie improved receptor function and signal transduction.
Piracetam enhances acetylcholine and glutamate (AMPA) signaling, increases cerebral glucose utilization and oxygen consumption in hypoxic conditions, and reduces vasospasm. Hemorheological effects—reduced platelet aggregation, decreased fibrinogen, increased red cell deformability—contribute to its use in vascular cognitive impairment.
- AMPA modulation: Allosteric enhancement of glutamate excitatory neurotransmission
- Membrane fluidity: Restores phospholipid bilayer dynamics in aged neurons
- Hemorheology: Reduces platelet aggregation and improves microcirculation
- Cholinergic: Enhances acetylcholine release and high-affinity choline uptake
- Neuroprotection: Reduces ischemic and oxidative damage in animal models
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Oral bioavailability | ~100% | Nearly complete absorption |
| Tmax | 30–60 minutes | Rapid onset |
| Half-life | 4–5 hours (plasma); 7–8 hours (CSF) | Multiple daily dosing required |
| Protein binding | None | Free fraction freely crosses BBB |
| Elimination | Renal, unchanged (>90%) | Dose-reduce in renal impairment |
Dosing & administration
Piracetam dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Piracetam is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Headache (often reversed by adding choline)
- • Insomnia or agitation
- • Nervousness
- • Gastrointestinal upset
- • Weight gain at high doses
Serious / potential risks
- • Increased bleeding risk
- • Psychomotor agitation
- • Hyperkinesia and aggression (rare, more common in elderly)
- • Hypersensitivity reactions
- • Caution in severe renal impairment
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Warfarin and anticoagulants | Increased bleeding risk via antiplatelet effect | Monitor INR; avoid in active bleeding |
| Thyroid hormone (T3/T4) | Reported confusion and tremor in combination | Use cautiously together |
| Carbamazepine | May potentiate seizure control in myoclonus | Often used together intentionally |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Piracetam is a nootropic compound with research interest in cognition, neuroprotection, memory, racetam. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive enhancement and neuroprotection
- • Individuals interested in cognition under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Winblad B.. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev (2005). doi: 10.1111/j.1527-3458.2005.tb00268.x PMID: 15992080
- [2] Flicker L, Grimley Evans G.. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev (2001). doi: 10.1002/14651858.CD001011 PMID: 11405971
- [3] Koskiniemi M, Van Vleymen B, Hakamies L, et al.. Piracetam relieves symptoms in progressive myoclonus epilepsy. J Neurol Neurosurg Psychiatry (1998). doi: 10.1136/jnnp.64.3.344 PMID: 9527147